Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protamine Dose Reduction in Aortic Valve Replacement
NCT06254404Not yet recruiting
- Sponsor
- University of Liège
- Start
- Mar 2024
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Randomised, single-blind trial of protamine in aortic valve disease (AVD) (2 arms), sponsored by University of Liège. Primary endpoint: Minimum effective dose of protamine after extracorporeal circulation (CP 50) at 24 hours. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
protamine
03
Conditions
aortic valve disease (AVD)
Beyond the preview
Go deeper on NCT06254404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254404.